Clinical trials
Hypertrophic Cardiomyopathy clinical trials
Below are recruiting hypertrophic cardiomyopathy clinical trials, each written for real people, not researchers. We’re tracking 75 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07420907Recruiting
Tracking heart health over time
This study uses a wearable patch to monitor heart-related signs in people with heart conditions. It aims to learn more about how these conditions progress, which could help improve future care.
Chicago, IllinoisAges 18 years+ - NCT06433050RecruitingEarly Phase 1
Testing a diabetes drug for nonobstructive hypertrophic cardiomyopathy
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
Philadelphia, PennsylvaniaAges 18 years+ - NCT03846297Recruiting
Decision support for defibrillator placement in hypertrophic cardiomyopathy
This trial looks at how to make better decisions about whether someone with hypertrophic cardiomyopathy (HCM) should get an implantable heart defibrillator. It may help by using structured decision support to guide defibrillator implantation.
Boulogne-Billancourt, Hauts-de-SeineAges 16 years+ - NCT04265040Recruiting
Heart muscle disease registry for non-ischemic conditions
This trial is a registry, meaning it collects health information to help doctors study heart muscle diseases and plan future cardiovascular studies. You may be able to join if you have a non-ischemic cardiomyopathy such as dilated cardiomyopathy, certain forms of thick heart muscle, non-compaction, or arrhythmogenic right-sided disease.
Heidelberg, Baden-WurttembergAges 18–80 - NCT05818605Recruiting
Exercise training for people with hypertrophic heart muscle
This study tests whether a 24-week exercise program can improve exercise tolerance in people with hypertrophic cardiomyopathy (a thickened heart muscle). You may be asked to use phone-based tools and complete surveys during training.
San Francisco, CaliforniaAges 18–80 - NCT07006493Recruiting
Radiofrequency ablation for obstructive hypertrophic cardiomyopathy
This trial tests a new treatment that uses radiofrequency energy (similar to heat) to shrink the thickened heart muscle blocking blood flow. It is for people with obstructive hypertrophic cardiomyopathy who have symptoms despite medication and are not able or willing to have heart surgery.
Beijing, Beijing MunicipalityAges 18–80 - NCT07021963RecruitingPhase 2
Long-term safety study of HRS-1893 for hypertrophic cardiomyopathy
This study tests the long-term safety of the drug HRS-1893 in people with hypertrophic cardiomyopathy who have already been in a previous HRS-1893 study. It helps doctors learn more about how safe the drug is over time.
Beijing, Beijing MunicipalityAges 18–85 - NCT07263204Recruiting
AI for diagnosing and predicting hypertrophic cardiomyopathy
This trial uses artificial intelligence to help diagnose and predict outcomes for people with hypertrophic cardiomyopathy (HCM), a condition where the heart muscle becomes thickened. It may help doctors better understand your condition and plan your care.
Hangzhou, ZhejiangAges 18 years+ - NCT02432092Recruiting
Genetic testing for heart muscle disease in children and families
This study looks at genetic (DNA) changes that may cause cardiomyopathy, a disease where the heart muscle is weakened. It may help families understand possible causes and inform future care.
Indianapolis, IndianaAges Any age - NCT07595354Recruiting
Safe Exercise Plan for Young People at Risk of Heart Disease
This study helps children and teens who may be at risk for a heart condition called HCM learn safe ways to exercise. Researchers will create a personalized exercise plan and check in regularly to see how it goes.
LiverpoolAges 10–18 - NCT07600177RecruitingPhase 4
Switching Heart Medicines: Mavacamten to Aficamten
This study tests switching from mavacamten to aficamten, two newer medicines that help improve heart function in people with a thickened heart muscle (HCM) that blocks blood flow. The goal is to see if aficamten works as well or better.
Kansas City, MissouriAges 18–90 - NCT06977646Enrolling by invitation
Heart surgery for apical hypertrophic cardiomyopathy without valve pressure
This study looks at people who have had surgery to reshape the left side of the heart for a specific type of thickened heart muscle (apical hypertrophic cardiomyopathy). It helps doctors understand how well this surgery works in patients without a large pressure difference across the heart valve.
Moscow, MoscowAges 15 years+ - NCT05100420Enrolling by invitation
HCM registry and DNA/imaging data collection study
This study collects health records, heart ultrasound (echo), MRI images, and optional DNA testing for people with hypertrophic cardiomyopathy (HCM). It aims to build a large database to better understand HCM and support future research and care.
Edmonton, AlbertaAges Any age - NCT03527342Enrolling by invitation
Sahlgrenska heart muscle disease study
This study focuses on people with certain “heart muscle” conditions (cardiomyopathies) to better understand them and guide care. If you have one of these specific diagnoses and are an adult, you may be able to take part.
GothenburgAges 18–99 - NCT05750147Recruiting
Study for cardiomyopathy linked to family or genes
This study looks at people with cardiomyopathy (or related heart muscle conditions) and those who may be at risk because of family history or genetic test results. It may help researchers better understand who is likely to develop the condition and how best to monitor or support them.
LondonAges Any age - NCT05884892Recruiting
Join a heart condition registry for hypertrophic cardiomyopathy
This program builds a registry of people diagnosed with hypertrophic cardiomyopathy and their family members. By collecting health information over time, researchers hope to better understand the condition and improve care.
AswānAges Any age - NCT06146660Recruiting
Mavacamten safety study in Korean patients with oHCM
This study checks how safe the drug mavacamten is for Korean patients with a type of heart disease called obstructive hypertrophic cardiomyopathy (oHCM). It is for people who are already prescribed the drug by their doctor.
SeoulAges 19 years+ - NCT06368518Recruiting
Study of hypertrophic cardiomyopathy in Austria
This study tracks people with hypertrophic cardiomyopathy, a heart muscle disease, to learn more about the condition and improve care. It does not test a new treatment but collects health information over time.
Linz, LinzAges 18 years+ - NCT06490250Recruiting
Breathing vs. movement exercises for hypertrophic cardiomyopathy
This study compares two types of gentle exercises—breathing muscle training and a traditional Chinese movement practice called Baduanjin—to see which helps people with hypertrophic cardiomyopathy feel better and improve their daily life. If you have a thickened heart muscle but are stable and have mild symptoms, you may be able to join.
IstanbulAges 18 years+ - NCT06580717RecruitingPhase 4
Testing empagliflozin for heart stiffness in hypertrophic cardiomyopathy
This study tests whether a diabetes drug (empagliflozin) can improve the heart's ability to relax and fill with blood in people with non-obstructive hypertrophic cardiomyopathy, a type of heart muscle thickening. You may be able to join if you have this condition and are not currently taking an SGLT2 inhibitor.
SeoulAges 19–80 - NCT06607471Recruiting
Study on non-ischemic heart muscle diseases
This study looks at different types of heart muscle diseases that are not caused by blocked arteries (non-ischemic cardiomyopathies). It aims to better understand how to diagnose, predict outcomes, and treat these conditions by gathering information from many patients over time.
Milan, MilanoAges 18 years+ - NCT07077005Recruiting
Can Mavacamten Help You Exercise More?
This study looks at whether taking mavacamten for at least 12 weeks helps people with a certain type of heart disease (hypertrophic obstructive cardiomyopathy) exercise better. You'll have tests to check your heart's function and safety during exercise.
Munich, BavariaAges 18–99 - NCT07150299Recruiting
How heart medications affect blood flow in hypertrophic cardiomyopathy
This study looks at how heart medications affect blood flow in people with obstructive hypertrophic cardiomyopathy. You will have a heart MRI before and after starting or adjusting treatment to see how your heart responds.
ViennaAges 18 years+ - NCT07367724RecruitingPhase 2
Ademetionine for obstructive hypertrophic cardiomyopathy
This trial tests a medication called Ademetionine for people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thick and blocks blood flow). It aims to see if the drug can help improve symptoms and exercise ability.
BeijingAges 18 years+
Hear when a new Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Hypertrophic Cardiomyopathy trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for hypertrophic cardiomyopathy?
- Yes. Clin2 currently lists 75 recruiting hypertrophic cardiomyopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hypertrophic cardiomyopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hypertrophic cardiomyopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.